Key result
Laparoscopic sleeve gastrectomy linked to a ~10 kg/m2 BMI reduction from baseline in obese patients.
Why the study?
Does laparoscopic sleeve gastrectomy improve BMI and obesity-associated comorbidities in obesity patients?
Observational (n=30)
Yes
Does laparoscopic sleeve gastrectomy improve BMI and obesity-associated comorbidities in obesity patients?
Mean Difference: 10.49 (95% CI 8.83–12.14)
Absolute Event Rate: 36.74% vs 47.23%
p-value: p=<0.001
Laparoscopic sleeve gastrectomy significantly reduces BMI and improves blood pressure and glycemic control in obese patients at short-term follow-up.
Supports short-term BMI reduction after sleeve gastrectomy; leaves open durability and comorbidity effects pending randomized trials.
BACKGROUND: Conservative methods for weight loss are usually disappointing. Therefore, surgeries such as Laparoscopic Sleeve Gastrectomy (LSG) should be considered. We aimed to evaluate the outcomes (body mass index; BMI) of LSG among obesity patients in the Northern West Bank. METHODS: Hospital records were reviewed for all patients who had undergone LSG since 2010 in Arab specialized hospital in Nablus and Palestinian Red Crescent society hospital in Tulkarem. Then, patients have been invited again to participate in the study and asked to self-report further pre-/post-operative measures. The primary study outcome was the change in BMI while secondary outcomes included obesity associated co-morbidities' measures; hypertension (HTN) and diabetes mellitus (DM). RESULTS: The mean age (standard deviation; SD) of the study participants (n = 30; 20 women and 10 men) was 34.06 (10.71) years. The mean (SD) follow-up time was 7.16 (5.05) months. The mean ± SD of the pre-operative BMI was 47.23 ± 7.89 kg/m2 while 36.74 ± 7.74 kg/m2 post-operatively (95% CI for mean differences and P-value; 8.83-12.14 and 0.001). For the clinically diagnosed hypertensive patients, there was a mean (SD) reduction of 27.50 (9.87) mm Hg in systolic pressure (P < 0.026) and 18.33 (13.66) of the diastolic blood pressure (P < 0.042). For diabetics, there were clinically and biologically clear mean (SD) reductions in fasting blood sugar and glycated hemoglobin A1c of about 82.00 (22.70) mg/dl and 1.90 (0.78) %; respectively. Only practicing sports or exercise (no/yes) remained significant with post-operative BMI (regression coefficient B = -7.33; P-value and 95% CI for B; 0.009 and -12.68- -1.98). CONCLUSIONS: LSG can significantly improve BMI and could improve or resolve obesity associated co-morbidities like HTN and DM. LSG could be recommended for co-morbid obesity patients who fail to reach beneficial results from a structured weight loss programs.
No takes yet. Share an insight, caveat, or question.
Zabadi et al. (2014) conducted an observational in Obesity (n=30). Laparoscopic sleeve gastrectomy vs. Pre-operative baseline was evaluated on Change in body mass index (BMI) (MD 10.49, 95% CI 8.83-12.14, p=<0.001). Laparoscopic sleeve gastrectomy significantly reduced body mass index by a mean of 10.49 kg/m2 compared to pre-operative baseline in obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: